文献速递冠心病血脂与心血管预防

他汀治疗与冠状动脉粥样硬化斑块成分进展的关联

Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque Composition.
PubMed 文献 · JAMA Cardiol · 2021-01-01

该队列研究纳入857例患者共2458处冠状动脉病变,连续行冠状动脉CT血管造影并定量分析斑块成分。他汀治疗与低衰减斑块和纤维脂肪斑块体积减少相关,并与高密度钙化斑块及1K斑块进展更明显相关。结果提示他汀使用与斑块向高密度钙化转化相关,钙化密度增加可能反映动脉粥样硬化风险降低。

要点

  • 他汀治疗与低衰减斑块和纤维脂肪斑块体积减少相关。
  • 他汀治疗与高密度钙化斑块及1K斑块进展更明显相关。
  • 基线无低衰减或纤维脂肪斑块的病变中,他汀与总钙化斑块体积变化无显著关联。

核心结论

  • 他汀使用与冠状动脉粥样硬化向高密度钙化转化率更高相关。
  • 随着钙化密度增加,总体斑块进展速度更慢。
  • 所有发现支持钙化密度增加与动脉粥样硬化风险降低相关的概念。

研究设计与样本

  • 这项队列研究纳入857例连续行冠状动脉CT血管造影(间隔2年或以上)并完成全冠状动脉树斑块定量测量的患者。
  • 研究于2013至2016年在7个国家13个中心开展,共分析2458处基线与随访匹配的冠状动脉病变。
  • 斑块成分按体素水平根据衰减值(Hounsfield单位,HU)分为6种类型,分析在2019年8月至2020年3月完成。

主要发现

  • 未治疗冠状动脉病变的6种成分斑块体积均随时间增加。

关键数值与推荐

  • 斑块成分按衰减值定义:低衰减(-30至75 HU)、纤维脂肪(76-130 HU)、纤维(131-350 HU)、低密度钙(351-700 HU)、高密度钙(701-1000 HU)和1K(>1000 HU)。
  • 基线斑块体积与钙密度交互分析显示,冠状动脉钙化越致密,斑块进展越少。

临床怎么用

  • 他汀治疗可能促进冠状动脉斑块向高密度钙化转化,提示斑块稳定。
  • 连续冠状动脉CT血管造影定量斑块成分有助于评估他汀治疗下的斑块进展模式。
  • 钙化密度增加可作为评估动脉粥样硬化风险降低的影像学参考。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The density of atherosclerotic plaque forms the basis for categorizing calcified and noncalcified morphology of plaques. OBJECTIVE: To assess whether alterations in plaque across a range of density measurements provide a more detailed understanding of atherosclerotic disease progression. DESIGN, SETTING, AND PARTICIPANTS: This cohort study enrolled 857 patients who underwent serial coronary computed tomography angiography 2 or more years apart and had quantitative measurements of coronary plaques throughout the entire coronary artery tree. The study was conducted from 2013 to 2016 at 13 sites in 7 countries. MAIN OUTCOMES AND MEASURES: The main outcome was progression of plaque composition of individual coronary plaques. Six plaque composition types were defined on a voxel-level basis according to the plaque attenuation (expressed in Hounsfield units [HU]): low attenuation (-30 to 75 HU), fibro-fatty (76-130 HU), fibrous (131-350 HU), low-density calcium (351-700 HU), high-density calcium (701-1000 HU), and 1K (>1000 HU). The progression rates of these 6 compositional plaque types were evaluated according to the interaction between statin use and baseline plaque volume, adjusted for risk factors and time interval between scans. Plaque progression was also examined based on baseline calcium density. Analysis was performed among lesions matched at baseline and follow-up. Data analyses were conducted from August 2019 through March 2020. RESULTS: In total, 2458 coronary lesions in 857 patients (mean [SD] age, 62.1 [8.7] years; 540 [63.0%] men; 548 [63.9%] received statin therapy) were included. Untreated coronary lesions increased in volume over time for all 6 compositional types. Statin therapy was associated with volume decreases in low-attenuation plaque (β, -0.02; 95% CI, -0.03 to -0.01; P = .001) and fibro-fatty plaque (β, -0.03; 95% CI, -0.04 to -0.02; P < .001) and greater progression of high-density calcium plaque (β, 0.02; 95% CI, 0.01-0.03; P < .001) and 1K plaque (β, 0.02; 95% CI, 0.01-0.03; P < .001). When analyses were restricted to lesions without low-attenuation plaque or fibro-fatty plaque at baseline, statin therapy was not associated with a change in overall calcified plaque volume (β, -0.03; 95% CI, -0.08 to 0.02; P = .24) but was associated with a transformation toward more dense calcium. Interaction analysis between baseline plaque volume and calcium density showed that more dense coronary calcium was associated with less plaque progression. CONCLUSIONS AND RELEVANCE: The results suggest an association of statin use with greater rates of transformation of coronary atherosclerosis toward high-density calcium. A pattern of slower overall plaque progression was observed with increasing density. All findings support the concept of reduced atherosclerotic risk with increased densification of calcium.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. van Rosendael AR, van den Hoogen IJ, Gianni U, et al. Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque Composition. JAMA Cardiol. 2021. PMID: 34406326. doi:10.1001/jamacardio.2021.3055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。